This search includes all content on the Scottish Parliament website, except for Votes and Motions. All Official Reports (what has been said in Parliament) and Questions and Answers are available from 1999. You can refine your search by adding and removing filters.
The Scottish rural road network is different in character to English "quiet lanes". The Transport (Scotland) Act does not include reference to quiet lanes as it was felt that they were not appropriate in the Scottish situation.
Although no separate assessment of the impact of the tax has been undertaken in Scotland, it is reasonable to expect a reduction in employers' costs to result in an increase in employment.
This may enable the Executive to produce the estimate you have asked for.So far this year there have been only two confirmed BSE cases found in Scotland. During the year 2000, 38 cases were identified.
Copies of the report, Hospital Acquired Infection - A Framework for a National System of Surveillance for the NHS in Scotland are available in the Parliament's Reference Centre.
To ask the Scottish Executive what financial impact the loss of Crown Exemption for police properties in respect of payment of non-domestic rates is expected to have on Central Scotland Police in 2001-02 and 2002-03.
In addition, the group has recently commissioned a survey to provide hard evidence of economic impacts, including employment effects, across all sectors and regions of Scotland. S1W-15222
The Scottish Executive believes that the outcome of the last round of discussions on EU Structural Funds represents a good deal for Scotland and the UK as well as the EU as a whole.
Questions and Answers
Date answered:
30 April 2001
The Reference was made on the basis of the criterion in section 123 of the Criminal Procedure (Scotland) Act 1995, namely that points of law had arisen in relation to the charges.
Questions and Answers
Date answered:
26 April 2001
Continuous hyper-fractionated accelerated radiotherapy (CHART) is not currently available in any of Scotland's five cancer centres.The National Institute for Clinical Excellence (NICE) has been asked to advise on the clinical and cost effectiveness of CHART for patients with inoperable non-small cell lung cancer.